Literature DB >> 20697116

Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival.

Evis Sala1, Masako Kataoka, Neeta Pandit-Taskar, Nicole Ishill, Svetlana Mironov, Chaya S Moskowitz, Oleg Mironov, Michelle A Collins, Dennis S Chi, Steven Larson, Hedvig Hricak.   

Abstract

PURPOSE: To compare accuracy and interobserver variability in the detection and localization of recurrent ovarian cancer with contrast material-enhanced (CE) computed tomography (CT) and positron emission tomography (PET)/CT and determine whether imaging findings can be used to predict survival.
MATERIALS AND METHODS: Waiving informed consent, the institutional review board approved this HIPAA-compliant, retrospective study of 35 women (median age, 54.4 years) with histopathologically proven recurrent ovarian carcinoma who underwent CE CT and PET/CT before exploratory surgery. All CE CT and PET/CT scans were independently analyzed. Tumor presence, number of lesions, and the size and maximum standardized uptake value (SUV(max)) of the largest lesion were recorded for patient and region. Surgical histopathologic findings constituted the reference standard. Areas under the receiver operating characteristic curves (AUCs), κ statistics, and hazard ratios were calculated.
RESULTS: Readers' AUCs in detection of recurrence for region were 0.85 (95% confidence interval [CI]: 0.81, 0.90) and 0.78 (95% CI: 0.72, 0.83) for CE CT and 0.84 (95% CI: 0.79, 0.89) and 0.74 (95% CI: 0.67, 0.81) for PET/CT (P = .76); 12 patients died. At PET/CT, size, number, and SUV(max) of peritoneal deposits were significantly associated with poor survival for readers 1 and 2 (P ≤ .01and ≤ .05, respectively), as were long- and short-axis diameters, number, and SUV(max) of distant lymph nodes for reader 1 (P ≤ .001). With CE CT, size (reader 1) and number (readers 1 and 3) of peritoneal deposits were significantly associated with poor survival (P ≤ .01), as were long- and short-axis diameters and number of distant lymph nodes for reader 1 (P ≤ .01). Interobserver agreement ranged from fair (patient, κ = 0.30) to moderate (region, κ = 0.55) for CE CT and fair (patient, κ = 0.24) to substantial (region, κ = 0.63) for PET/CT.
CONCLUSION: Preliminary data suggest that CE CT and PET/CT may have similar accuracy in detection of recurrent ovarian cancer. Tumor size, number, and SUV(max) may have potential as prognostic biomarkers for patients with recurrent ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697116      PMCID: PMC3726307          DOI: 10.1148/radiol.10092279

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  28 in total

Review 1.  PET-CT in recurrent ovarian cancer: initial observations.

Authors:  Harpreet K Pannu; Robert E Bristow; Christian Cohade; Elliot K Fishman; Richard L Wahl
Journal:  Radiographics       Date:  2004 Jan-Feb       Impact factor: 5.333

2.  Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma.

Authors:  R A Kubik-Huch; W Dörffler; G K von Schulthess; B Marincek; O R Köchli; B Seifert; U Haller; H C Steinert
Journal:  Eur Radiol       Date:  2000       Impact factor: 5.315

3.  Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?

Authors:  B Patsner; J W Orr; W J Mann; P T Taylor; E Partridge; T Allmen
Journal:  Gynecol Oncol       Date:  1990-09       Impact factor: 5.482

Review 4.  Surgery for recurrent ovarian cancer.

Authors:  P G Rose
Journal:  Semin Oncol       Date:  2000-06       Impact factor: 4.929

5.  Peritoneal metastases: detection with spiral CT in patients with ovarian cancer.

Authors:  Fergus V Coakley; Patricia H Choi; Christina A Gougoutas; Bhavana Pothuri; Ennapadam Venkatraman; Dennis Chi; Antonina Bergman; Hedvig Hricak
Journal:  Radiology       Date:  2002-05       Impact factor: 11.105

6.  Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.

Authors:  G A Omura; M F Brady; H D Homesley; E Yordan; F J Major; H J Buchsbaum; R C Park
Journal:  J Clin Oncol       Date:  1991-07       Impact factor: 44.544

7.  Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Domeki; Yasushi Kaji; Ichio Fukasawa; Noriyuki Inaba; Narufumi Suganuma; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-17       Impact factor: 9.236

8.  Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure.

Authors:  J J Folk; M Botsford; A G Musa
Journal:  Gynecol Oncol       Date:  1995-05       Impact factor: 5.482

9.  Normal pelvic lymph nodes: evaluation with CT after bipedal lymphangiography.

Authors:  S J Vinnicombe; A R Norman; V Nicolson; J E Husband
Journal:  Radiology       Date:  1995-02       Impact factor: 11.105

10.  Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer.

Authors:  S C Rubin; W J Hoskins; T B Hakes; M Markman; B S Reichman; D Chapman; J L Lewis
Journal:  Am J Obstet Gynecol       Date:  1989-03       Impact factor: 8.661

View more
  16 in total

1.  Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration.

Authors:  Olivio F Donati; Yulia Lakhman; Evis Sala; Irene A Burger; Hebert A Vargas; Debra A Goldman; Vaagn Andikyan; Kay J Park; Dennis S Chi; Hedvig Hricak
Journal:  Eur Radiol       Date:  2013-05-08       Impact factor: 5.315

Review 2.  An update on the role of PET/CT and PET/MRI in ovarian cancer.

Authors:  Benjapa Khiewvan; Drew A Torigian; Sahra Emamzadehfard; Koosha Paydary; Ali Salavati; Sina Houshmand; Thomas J Werner; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-08       Impact factor: 9.236

3.  HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma.

Authors:  Cecilia Midulla; Lucia Manganaro; Flavia Longo; Valentina Viggiani; Luigi Frati; Teresa Granato; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-03-20

Review 4.  Molecular Imaging of Ovarian Cancer.

Authors:  Sai Kiran Sharma; Brandon Nemieboka; Evis Sala; Jason S Lewis; Brian M Zeglis
Journal:  J Nucl Med       Date:  2016-04-28       Impact factor: 10.057

5.  Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients.

Authors:  Laura Evangelista; Maurizia Dalla Palma; Michele Gregianin; Margherita Nardin; Anna Roma; Maria Ornella Nicoletto; Giovanni Battista Nardelli; Vittorina Zagonel
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-08-06

6.  The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.

Authors:  N L Robertson; H Hricak; Y Sonoda; R E Sosa; M Benz; G Lyons; N R Abu-Rustum; E Sala; H A Vargas
Journal:  Gynecol Oncol       Date:  2016-01-11       Impact factor: 5.482

Review 7.  Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.

Authors:  Mayur Virarkar; Dhakshinamoorthy Ganeshan; Anjalie Tara Gulati; Sarah Palmquist; Revathy Iyer; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11-11

8.  Prediction of chemotherapy response in ovarian cancer patients using a new clustered quantitative image marker.

Authors:  Abolfazl Zargari; Yue Du; Morteza Heidari; Theresa C Thai; Camille C Gunderson; Kathleen Moore; Robert S Mannel; Hong Liu; Bin Zheng; Yuchen Qiu
Journal:  Phys Med Biol       Date:  2018-08-06       Impact factor: 3.609

9.  Evaluation of CA-125 as an Indicator of Imaging During Follow-up of Carcinoma Ovary: Original Research.

Authors:  Pesona Grace Lucksom; Sonia Mathai; Jaydip Bhaumik; Anik Ghosh
Journal:  J Obstet Gynaecol India       Date:  2020-05-12

10.  Diagnosis and management of peritoneal metastases from ovarian cancer.

Authors:  Evgenia Halkia; John Spiliotis; Paul Sugarbaker
Journal:  Gastroenterol Res Pract       Date:  2012-07-19       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.